Annual Review of Medicine,
Год журнала:
2021,
Номер
73(1), С. 129 - 147
Опубликована: Авг. 11, 2021
The
prevalence
of
diabetes
in
people
with
coronavirus
disease
2019
(COVID-19),
caused
by
severe
acute
respiratory
syndrome
coronavirus-2
(SARS-CoV-2),
has
varied
worldwide.
Most
the
available
evidence
suggests
a
significant
increase
severity
and
mortality
COVID-19
either
type
1
(T1DM)
or
2
mellitus
(T2DM),
especially
association
poor
glycemic
control.
While
new-onset
hyperglycemia
(both
T1DM
T2DM)
have
been
increasingly
recognized
context
associated
worse
outcome,
no
conclusive
yet
direct
tropism
SARS-CoV-2
on
β
cells
pancreatic
islets.
all
approved
oral
antidiabetic
agents
appear
to
be
safe
T2DM
having
COVID-19,
data
are
indicate
benefit
any
class
these
drugs,
absence
large
randomized
controlled
trials.
Frontiers in Cardiovascular Medicine,
Год журнала:
2021,
Номер
8
Опубликована: Фев. 17, 2021
Coronavirus
disease
2019
(COVID-19)
has
become
a
worldwide
pandemic
responsible
for
millions
of
deaths
around
the
world.
Hypertension
been
identified
as
one
most
common
comorbidities
and
risk
factors
severity
adverse
outcome
in
these
patients.
Recent
investigations
have
raised
question
whether
hypertension
represents
predictor
COVID-19
patients
independently
other
such
diabetes,
obesity,
cardiovascular
diseases,
chronic
kidney,
liver,
pulmonary
diseases.
However,
impact
newly
diagnosed
insufficiently
investigated.
The
same
is
true
relationship
between
blood
pressure
levels
outcomes
It
seems
that
long
discussion
about
angiotensin-converting
enzyme
inhibitors
(ACEI)
blockers
angiotensin
I
receptors
(ARB)
on
approaching
an
end
because
large
number
original
studies
meta-analyses
discarded
initial
findings
higher
prevalence
ACEI/ARB
use
with
unfavorable
outcomes.
Nevertheless,
there
are
many
controversies
COVID-19.
aim
this
review
article
to
provide
clinical
overview
currently
available
evidence
regarding
predictive
value
hypertension,
effect
levels,
previously
known
antihypertensive
therapy
Cell Reports,
Год журнала:
2022,
Номер
38(11), С. 110508 - 110508
Опубликована: Фев. 21, 2022
Concerns
that
infection
with
severe
acute
respiratory
syndrome
coronavirus
2
(SARS-CoV-2),
the
etiological
agent
of
disease
2019
(COVID-19),
may
cause
new-onset
diabetes
persist
in
an
evolving
research
landscape,
and
precise
risk
assessment
is
hampered
by,
at
times,
conflicting
evidence.
Here,
leveraging
comprehensive
single-cell
analyses
vitro
SARS-CoV-2-infected
human
pancreatic
islets,
we
demonstrate
productive
strictly
dependent
on
SARS-CoV-2
entry
receptor
ACE2
targets
practically
all
cell
types.
Importantly,
remains
highly
circumscribed
largely
non-cytopathic
and,
despite
a
high
viral
burden
infected
subsets,
promotes
only
modest
cellular
perturbations
inflammatory
responses.
Similar
experimental
outcomes
are
also
observed
after
islet
endemic
coronaviruses.
Thus,
limits
infection,
even
under
conditions
enhanced
virus
exposure,
challenge
proposition
vivo
targeting
β
cells
by
precipitates
diabetes.
Whether
restricted
damage
immunological
alterations
accrued
COVID-19
increase
cumulative
risk,
however,
to
be
evaluated.
Scientific Reports,
Год журнала:
2023,
Номер
13(1)
Опубликована: Апрель 19, 2023
Abstract
A
COVID-19
patient
often
presents
with
multiple
comorbidities
and
is
associated
adverse
outcomes.
comprehensive
assessment
of
the
prevalence
in
patients
essential.
This
study
aimed
to
assess
comorbidities,
severity
mortality
regard
geographic
region,
age,
gender
smoking
status
COVID-19.
systematic
review
multistage
meta-analyses
were
reported
using
PRISMA
guidelines.
PubMed/MEDLINE,
SCOPUS,
Google
Scholar
EMBASE
searched
from
January
2020
October
2022.
Cross-sectional
studies,
cohort
case
series
case–control
studies
on
reporting
among
populations
that
published
English
included.
The
pooled
various
medical
conditions
was
calculated
based
regional
population
size
weights.
Stratified
analyses
performed
understand
variations
gender,
region.
total
190
comprising
105
million
Statistical
STATA
software,
version
16
MP
(StataCorp,
College
Station,
TX).
Meta-analysis
proportion
obtain
values
comorbidities:
hypertension
(39%,
95%
CI
36–42,
n
=
170
studies),
obesity
(27%,
25–30%,
169
diabetes
175),
asthma
(8%,
7–9%,
112).
Moreover,
hospitalization
35%
(95%
29–41%,
61),
intensive
care
admissions
17%
14–21,
106),
18%
16–21%,
145).
highest
Europe
at
44%
39–47%,
68),
30%
CI,
26–34,
79)
27%
(95%CI,
24–30,
80)
North
America,
9%
8–11,
41).
Obesity
high
≥
50
years
(30%,
112)
age
group,
Men
(26%,
124)
observational
higher
than
(19%
vs.
14%).
Random
effects
meta-regression
found
a
significant
association
between
(
p
<
0.001),
0.05),
ICU
admission
0.05)
0.001).
Overall,
global
(39%)
lower
(8%),
Hence,
geographical
regions
respective
chronic
should
accelerate
regular
booster
dose
vaccination,
preferably
those
prevent
disease
novel
SARS-CoV-2
variants
concern
(VOC).
